Insider Trading March 26, 2026

Axcelis CEO Sells $111,960 in Stock as Company Tops Q4 Estimates but Issues Softer Q1 Guidance

Russell Low executed a planned 10b5-1 sale; Axcelis beat fourth-quarter estimates while naming an interim CFO and seeing an external CFO hire at Hexcel.

By Priya Menon ACLS
Axcelis CEO Sells $111,960 in Stock as Company Tops Q4 Estimates but Issues Softer Q1 Guidance
ACLS

Russell Low, President and CEO of Axcelis Technologies Inc (NASDAQ: ACLS), sold 1,244 shares on March 24, 2026, under a Rule 10b5-1 plan established in December 2025. The transaction totaled $111,960 at $90.00 per share. Axcelis reported stronger-than-expected fourth-quarter results but issued first-quarter guidance below analyst expectations. Concurrently, the company announced an interim CFO appointment as its outgoing finance chief prepares to join another firm.

Key Points

  • Axcelis CEO Russell Low sold 1,244 shares on March 24, 2026 under a Rule 10b5-1 plan for $111,960 at $90.00 per share.
  • Axcelis beat Q4 estimates with adjusted EPS of $1.49 and $238.33 million in revenue, helped by record customer support and installation revenue.
  • The company issued Q1 guidance below analyst expectations and named David Ryzhik Interim CFO as James Coogan transitions to a CFO role at another firm and will assist through April 24.

Insider transaction details

Russell Low, who serves as President and Chief Executive Officer of Axcelis Technologies Inc (NASDAQ: ACLS), disposed of 1,244 shares of the company's common stock on March 24, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at $90.00 per share, producing a total transaction value of $111,960. The filing specifies that the sale was carried out under a Rule 10b5-1 trading plan Low adopted on December 11, 2025.

Post-transaction holdings and restricted stock units

Following the sale, Low is reported to directly own 133,526 shares of Axcelis Technologies. Of that holding, 83,480 shares are noted as issuable upon the vesting of restricted stock units granted under the company’s 2012 Equity Incentive Plan; those shares remain subject to forfeiture under the terms of the grant.

Share-price context

Since the March 24 transaction, the company's share price has risen to $98.35 and is trading near a 52-week high of $102.93. Over the past 12 months, Axcelis shares have delivered a 77% return.

Fourth-quarter financial results

In its most recent reporting period, Axcelis posted adjusted earnings of $1.49 per share for the fourth quarter, ahead of the analyst consensus of $1.12. Revenue for the quarter reached $238.33 million, above the consensus estimate of $215.03 million. The company attributed the revenue beat largely to record customer support and installation revenue.

Near-term outlook and guidance

Despite the stronger-than-expected fourth-quarter performance, Axcelis issued first-quarter guidance that fell short of analyst expectations. The company did not provide additional detail in the filing beyond noting the guidance miss.

Leadership changes at Axcelis and Hexcel

Axcelis announced a leadership update in conjunction with its results. David Ryzhik has been appointed Interim Chief Financial Officer at Axcelis, succeeding James Coogan. Coogan is set to transition to a chief financial officer role at another company and will remain with Axcelis to assist in the transition through April 24.

Separately, Hexcel Corporation disclosed that James Coogan will join its ranks as Executive Vice President and Chief Financial Officer, effective May 1, 2026. At Hexcel, Coogan will report to Tom Gentile, who serves as Chairman, Chief Executive Officer, and President. Coogan will replace Mike Lenz, who had been serving as interim CFO; Lenz will stay with Hexcel as a Senior Advisor to support the handover.

Concluding context

The insider sale by Axcelis' CEO occurred alongside a quarterly beat on both earnings and revenue, a subsequent quarterly guidance shortfall, and near-term financial leadership transitions at two companies. The filings and corporate announcements provide the factual record of the trade, the company results, and the executive moves.


Key points

  • Axcelis CEO Russell Low sold 1,244 shares on March 24, 2026, for $111,960 at $90.00 per share under a Rule 10b5-1 plan adopted December 11, 2025.
  • Axcelis beat fourth-quarter estimates with adjusted EPS of $1.49 and revenue of $238.33 million, driven by record customer support and installation revenue.
  • The company issued first-quarter guidance below analyst expectations and announced David Ryzhik as Interim CFO while James Coogan transitions to a CFO role at another company; Coogan will help with the transition through April 24.

Risks and uncertainties

  • First-quarter guidance from Axcelis fell short of analyst expectations - a near-term forecasting risk for semiconductor equipment and related industrial sectors.
  • Changes in senior financial leadership at Axcelis and the move of a finance executive to Hexcel introduce transitional uncertainty in both companies' financial management.
  • Insider sales, even when executed under pre-established plans, can be interpreted variably by investors and may affect short-term sentiment in the stock market for semiconductor-related equities.

Risks

  • First-quarter guidance that missed analyst expectations introduces near-term forecasting risk for semiconductor equipment and industrial sectors.
  • Financial leadership transitions at Axcelis and the incoming CFO role at Hexcel create uncertainty during executive handovers.
  • Insider stock sales, even under Rule 10b5-1 plans, may influence investor perception and short-term trading dynamics in semiconductor-related equities.

More from Insider Trading

DXP Enterprises Director Sells $697,850 of Stock as Shares Trade Near Yearly Highs Mar 26, 2026 Magnetar Financial Sells 8,840 WHLR Shares for $9,692 as Wheeler REIT Faces Leadership, Capital-Structure Moves Mar 26, 2026 Definium Therapeutics CLO Sells $197,665 in Stock to Cover Tax Withholding Mar 26, 2026 Definium Therapeutics CEO Executes $451K Share Sale; Company Reiterates R&D Focus Mar 26, 2026 Definium Therapeutics CMO Sells Shares to Cover Taxes; Company Reiterates R&D Focus After Q4 2025 Results Mar 26, 2026